MedTrace Logo

TachoSil Paediatric Liver Trial (TC-019-IN)

NCT00365248 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2012-05-07

No results posted yet for this study

Summary

The overall objective is to assess the haemostatic efficacy and safety of TachoSil for control of local bleeding in paediatric patients undergoing surgical resection of the liver with our without segmental liver transplantation.

Conditions

Interventions

DRUG

Fibrinogen human (TachoSil)

Resection of the liver with or without segmental liver transplantation

Sponsors & Collaborators

  • Nycomed

    lead INDUSTRY

Principal Investigators

  • Clinical Trial Operations · Headquaters

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
4 Weeks
Max Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Completion
2008-05-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00365248 on ClinicalTrials.gov